DELFI-TF

About DELFI Diagnostics

DELFI Diagnostics is a private, pre-revenue diagnostics company pioneering a novel approach to early cancer detection through fragmentomics—the analysis of cfDNA fragmentation patterns. Its core technology uses machine learning to scan millions of data points from a simple blood draw, aiming to detect cancer signals without relying solely on known mutations. The company is led by an experienced team with backgrounds from Illumina, GRAIL, and major academic institutions and is currently advancing its first product, FirstLook Lung, through clinical validation.

Therapeutic Areas